-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | None |
| Beta | nan |
|---|---|
| Market Cap | None |
| PE Ratio | nan |
| Target Price | nan |
| Dividend Yield | nan% |
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LIMNW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025